FDA Approves Cabozantinib for Renal Cell CarcinomaFDA Approves Cabozantinib for Renal Cell Carcinoma

As a second-line therapy for advanced disease, it has recently been shown to improve survival. But is it a better choice than nivolumab? FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news